Indications

• Metastatic Melanoma with BRAF V600E Gene Mutation (see Melanoma, [[Melanoma]]): used in combination with the MEK inhibitor Trametinib (Mekinist) (see Trametinib, [[Trametinib]]), due to resistance to Dabrafenib which develops within 6-7 mo
  • FDA approved for this indication May 30, 2013

Pharmacology

• BRAF (B-raf) Enzyme Inhibitor: BRAF plays a role in the regulation of cell growth

Administration

• xxx

Adverse Effects

Other Adverse Effects

• xxxx

References

• xxx